Clinical Predictors of Acute Response With Quetiapine in Psychotic Mood Disorders
J Clin Psychiatry 2000;61:185-189
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: In controlled studies of
patients with schizophrenia, the atypical antipsychotic
quetiapine, 300 mg/day, has been shown to be as effective in the
treatment of positive and negative symptoms as haloperidol.
However, little is known about the efficacy of quetiapine in
patients with psychotic mood disorders. The purpose of this study
was to assess the efficacy of quetiapine in the treatment of
psychotic mood disorders in comparison with nonaffective
psychotic disorders and identify clinical factors associated with
Method: In a naturalistic setting, by
reviewing medical records, we assessed response to quetiapine and
factors associated with response to quetiapine in 145 consecutive
patients newly treated with the drug at a nonprofit academic
psychiatric hospital. These patients had received a discharge
diagnosis of bipolar disorder (manic, mixed, or depressive type),
major depression with psychotic features, schizophrenia,
schizoaffective disorder (bipolar or depressive type), delusional
disorder, or psychosis not otherwise specified (NOS) according to
Results: Patients with a diagnosis of bipolar
disorder, manic, mixed, or depressed and schizoaffective
disorder, bipolar type displayed higher response rates (> 74%)
compared with patients with schizophrenia. However, this finding
did not achieve statistical significance. A diagnosis of major
depression with psychotic features (p = .02) and longer duration
of illness (p = .03) were associated with less chance of
Conclusion: Quetiapine may be a useful
alternative or adjunctive treatment for patients with bipolar and